The purpose of this study was to test whether different results between Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON (CHAMPION) PCI/PLATFORM and PHOENIX trials are due in part to different definitions of percutaneous coronary intervention (PCI)-related myocardial infarction (MI).In patients with acute coronary syndrome (ACS), the definition of MI was identical in CHAMPION PCI and PLATFORM and did not require an assessment of baseline cardiac biomarker status, while in PHOENIX specific MI criteria were associated with different patient presentations. The same MI criteria were used in PCI, PLATFORM, and PHOENIX for patients with stable angina. Logistic regression assessed the effect of cangrelor on MI (PCI- and non-PCI related) in the combined PCI/PLATFORM population and in PHOENIX. Consistency of cangrelor's effect in PCI/PLATFORM and in PHOENIX in patients with stable angina and in those with an ACS (with or without ST elevation) was evaluated. Overall, the incidence of PCI-related MI at 48 h was 6.3

作者：Sergio, Leonardi；Renato D, Lopes；Ph Gabriel, Steg；Freddy, Abnousi；Alberto, Menozzi；Jayne, Prats；Stacey, Mangum；Matthew, Wilson；Meredith, Todd；Gregg W, Stone；C Michael, Gibson；Christian W, Hamm；Matthew J, Price；Harvey D, White；Robert A, Harrington；Deepak L, Bhatt；Kenneth W, Mahaffey

来源：European heart journal. Acute cardiovascular care 2016 年